Long-term results show Opdivo combined with Yervoy outlasts Sunitinib in survival outcomes for advanced or metastatic kidney cancer patients who haven't received prior treatment over an 8-year period.

Vanda Pharmaceuticals Granted Green Light by FDA to Advance with Experimental Antisense Oligonucleotide Therapy, VCA-894A, for Managing Charcot-Marie-Tooth Disease, Subtype 2S.

Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.

Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.

Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.

Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.

NK CellTech has received the green light from the Food and Drug Administration (FDA) to initiate clinical trials for its therapy, NK010.

ProMIS Neurosciences Inc. has declared the identification of a premier vaccine contender, PMN400.

AC Immune SA to Reclaim Global Ownership of Two Therapeutic Antibodies Post-Partnership with Genentech and Roche.